SCHEMBL6845508

SCHEMBL6845508

c1cncc(-n2ccc3ccc(-c4ccsc4)cc32)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 3/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2B6 P20813 1/20 0.50
CYP2C19 P33261 1/20 0.50
HTR1D P28221 2/20 0.45
HDAC1 Q13547 1/20 0.41
HTR7 P34969 1/20 0.41
PPARA Q07869 1/20 0.40
BACE1 P56817 1/20 0.38
HTR6 P50406 3/20 0.37
MAPT P10636 2/20 0.37
NPC1 O15118 1/20 0.36
CYP19A1 P11511 2/20 0.36
CYP11B1 P15538 2/20 0.36
CYP11B2 P19099 2/20 0.36
FYN P06241 1/20 0.36
CYP17A1 P05093 1/20 0.36
PDGFRB P09619 1/20 0.36
PDGFRA P16234 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6663147 0.90 CYP2A6 (0.50) CYP2A6CYP3A4CYP2C9CYP2B6CYP2C19
SCHEMBL6844272 0.85 HTR6 (0.50) CYP2A6CYP3A4HTR1DHTR6MAPT
SCHEMBL6846150 0.84 HTR1D (0.55) CYP2A6CYP3A4HTR1DMAPTCYP19A1
SCHEMBL6846114 0.82 HTR1D (0.48) HTR1DHTR6MAPTCYP19A1CYP11B1
SCHEMBL6658140 0.80 CYP19A1 (0.55) CYP3A4HTR1DHTR6MAPTNPC1
SCHEMBL6661324 0.79 HTR1D (0.46) CYP2A6CYP3A4CYP2C9CYP2B6CYP2C19
SCHEMBL6659322 0.78 HTR1D (0.47) CYP2A6CYP3A4HTR1DMAPTCYP19A1
SCHEMBL6660867 0.78 MAPT (0.46) HTR1DMAPTCYP19A1CYP11B1CYP11B2
SCHEMBL6846000 0.77 CDC7 (0.43) HTR1DHTR6MAPTNPC1CYP19A1
SCHEMBL6844445 0.77 CYP2A6 (0.47) CYP2A6CYP3A4CYP2C9CYP2B6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors BAYER PHARMACEUTICALS CORPORATION 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors CYP17A1, IDO1, CYP21A2 CYP2A6 182/4885CYP3A4 98/4885CYP2C9 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.